Belatacept: a new era of immunosuppression?
Expert Rev Clin Immunol
; 8(6): 527-36, 2012 Aug.
Article
in En
| MEDLINE
| ID: mdl-22992146
ABSTRACT
Full T-cell activation in alloimmunity requires the engagement of several costimulatory molecules. CTLA-4-Ig and its commercially available fusion proteins, belatacept and abatacept, are used to block CD80/86 and promote T-cell tolerance. Belatacept, a higher binding affinity molecule, is currently approved for clinical use in renal transplantation. The results of two Phase III clinical trials showed a similar patient/graft survival, with better renal function at a 3-year follow-up compared with conventional immunosuppression. There was a higher risk of early rejection and post-transplant lymphoproliferative disorder, especially with EBV-negative patients receiving kidneys from EBV-positive donors. Belatacept-treated groups had a better cardiovascular and metabolic profile. The authors review both preclinical and human studies of CTLA-4-Igs.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Kidney Transplantation
/
Immunoconjugates
/
Immunosuppressive Agents
Limits:
Animals
/
Humans
Language:
En
Journal:
Expert Rev Clin Immunol
Journal subject:
ALERGIA E IMUNOLOGIA
Year:
2012
Type:
Article
Affiliation country:
United States